NDAINTRAUTERINESYSTEM1 Generic Approved
Approved
Jan 2013
Lifecycle
Peak
Competitive Pressure
23/100
Clinical Trials
20
Data completeness
5/8 — Partial
SKYLA (levonorgestrel) by Bayer. Approved for progestin [epc]. First approved in 2013.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SKYLA is a levonorgestrel-releasing intrauterine system (IUS) approved in 2013 for contraception and menorrhagia. It works through multiple mechanisms including thickening cervical mucus to inhibit sperm passage, reducing sperm mobility, and altering the endometrium. The product is indicated across a broad spectrum including contraception, menorrhagia, dysmenorrhea, adenomyosis, and off-label uses in epilepsy, HIV, and malignancy management.
$13KPart D
Peak3.4 years to LOESKYLA operates in peak lifecycle with extremely modest Medicare Part D penetration ($13K spending), suggesting significant opportunity in commercial markets and international expansion for established brand and sales teams.
Mechanism of Action
Pharmacologic Class:
Progestin
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
Started May 2026
24 enrolled
Healthy Participants
A Study to Evaluate the Efficacy and Safety of Subcutaneous Levonorgestrel Butanoate for Female Contraception
Started Apr 2026
165 enrolled
Healthy WomenFemale Contraception
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Started Mar 2026
16 enrolled
Healthy Volunteer
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
Started Dec 2025
24 enrolled
Healthy Volunteer Study
A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity
Started Jun 2025
50 enrolled
Healthy Participants
Worked on SKYLA at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.